Maurice Bernaiche, DO
Interventional Pain Medicine · Thomasville, GANPI 1407824576
Payments from drug & device makers
Across 349 payments — averaging $33.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biodelivery Sciences International, Inc.$6K
- Collegium Pharmaceutical, Inc.$1K
- Nevro Corp.$857
- Abbott$825
- Boston Scientific$491
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$466
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$5,38046%
- Travel & lodging$1872%
- Food & beverage$6,17452%
- Education$450%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biodelivery Sciences International, Inc. | 18 | $5,867 |
| Collegium Pharmaceutical, Inc. | 68 | $1,139 |
| Nevro Corp. | 22 | $857 |
| Abbott | 61 | $825 |
| Boston Scientific | 15 | $491 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 42 | $466 |
| Scilex Pharmaceuticals Inc. | 31 | $454 |
| Almatica Pharma LLC | 15 | $239 |
| Medtronic(2 entities) | 9 | $185 |
| Globus Medical | 7 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $92 |
| AbbVie | 3 | $73 |
| Lilly USA, LLC | 4 | $71 |
| Bioventus LLC | 3 | $65 |
| Vertex | 3 | $58 |
| Pacira Pharmaceuticals Incorporated | 3 | $56 |
| Assertio Therapeutics, Inc. | 3 | $54 |
| Eisai Inc. | 3 | $51 |
| Sentynl Therapeutics, Inc. | 3 | $51 |
| Amgen(2 entities) | 2 | $48 |
| CSL Behring | 3 | $48 |
| Redhill Biopharma Inc. | 3 | $45 |
| Lundbeck LLC | 2 | $43 |
| Vertos Medical, Inc. | 1 | $42 |
| Pacira Therapeutics, Inc. | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| AstraZeneca | 1 | $26 |
| Relievant Medsystems, Inc. | 1 | $26 |
| Averitas Pharma Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Neurelis, Inc. | 1 | $18 |
| Indivior Inc. | 1 | $18 |
| Sanofi | 1 | $18 |
| Fidia Pharma USA Inc. | 1 | $17 |
| Pfizer | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BELBUCA$4,675
- SPECTRA WAVEWRITER$111
- Senza$110
How this compares
$11,786 in reported general payments places this provider in the 75th percentile of 129 interventional pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 3,411 | $119,088 |
| BelbucaBuprenorphine Hcl | 109 | $93,879 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 2,267 | $82,644 |
| Buprenorphine | 233 | $63,354 |
| LinzessLinaclotide | 73 | $45,743 |
| ZtlidoLidocaine | 79 | $38,172 |
| Xtampza ErOxycodone Myristate | 65 | $31,682 |
| MovantikNaloxegol Oxalate | 55 | $24,274 |
| Nucynta ErTapentadol Hcl | 24 | $17,913 |
| Oxycodone Hcl | 790 | $13,667 |
| Hysingla ErHydrocodone Bitartrate | 30 | $11,276 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 44 | $7,861 |
| Gabapentin | 384 | $5,463 |
| Pregabalin | 257 | $5,355 |
| Morphine Sulfate ErMorphine Sulfate | 200 | $4,665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er | $1,139 | $143,474198 claims |
| AbbVieLinzess | $73 | $45,74373 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $454 | $38,17279 claims |
| Redhill Biopharma Inc.Movantik | $45 | $24,27455 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 129 interventional pain medicine providers in Georgia.
Other interventional pain medicine in Thomasville
- Maximilian ShokatThomasville$7K
- Marvin TarkMarietta$3.6M
- Jordan TateJasper$764K
- Emmanuel GageBrunswick$648K
- Christopher BovinetBrunswick$356K
- D Terrence FosterStockbridge$305K
- David RosenfeldCovington$287K
- Nathan NeufeldNewnan$171K
- Ryan BudwanyLawrenceville$123K
- Alexandra MoreiraAtlanta$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.